Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma.
Prognosis of relapsed and refractory neuroblastoma is uniformly fatal; new therapeutic approaches are needed. Relapsed and refractory neuroblastoma patients were treated with continuous infusion chemotherapy combined with MIBG. Over 4 years, 35 heavily pretreated patients were registered, 29 with bone or/and bone marrow metastases. Grade 3 or 4 hematologic toxicity was frequent, without toxic deaths. Sixteen patients responded. The probability of 5-year overall survival was 0.19. This approach is feasible and toxicity manageable; it rescued some patients and prolonged their survival. It merits assay in newly diagnosed high-risk neuroblastoma patients.